無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

マイクロバイオーム治療薬の世界市場の分析 (2018年)

Global Microbiome Therapeutics Market Research Report 2018

発行 QYResearch 商品コード 600598
出版日 ページ情報 英文 168 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=113.03円で換算しております。
Back to Top
マイクロバイオーム治療薬の世界市場の分析 (2018年) Global Microbiome Therapeutics Market Research Report 2018
出版日: 2018年01月19日 ページ情報: 英文 168 Pages
概要

近年、世界各国でマイクロバイオーム治療薬の開発に向けた動きが活発化しており、年率98%もの速度で市場が急速に成長しています。世界のマイクロバイオーム治療薬の市場規模は、2017年には約1400万米ドルに達しています。また、年間開発投資額は2017年には2億930万米ドルにまで拡大する見込みです。治験段階別に見ると、第III相の製品が2種類、第II相の製品が7種類、第I相の製品が8種類、前臨床段階の製品が17種類存在しています。

当レポートでは、世界のマイクロバイオーム治療薬市場における治験・販売状況について分析し、医薬品の主な対象領域・疾患や、市場規模および研究開発 (R&D) 投資額の動向見通し (過去・今後6年間分)、地域別・種類別・用途別の詳細動向、製品コスト構造、関連産業との関連性、市場競争環境、治験中の主要製品 (パイプライン製品) の現在の治験段階、主要企業のプロファイル・業績、今後の市場機会・課題などを調査しております。

第1章 マイクロバイオーム治療薬市場の概要

  • 製品概要
  • 用途別の内訳
    • R&D投資額・増加率の相互比較:用途別 (通算11年間分)
    • R&D投資額シェア:種類別
    • CDI (クロストリジウム・ディフィシル感染症)
    • 炎症性腸疾患 (IBD)
    • 希用薬
    • がん免疫療法
  • マイクロバイオーム治療薬市場:パイプライン別
  • 地域別の内訳 (通算11年間分)
    • 市場規模・成長率の相互比較:地域別 (金額ベース、通算11年間分)
    • 北米市場の現状と見通し (通算14年間分)
    • アジア太平洋地域市場の現状と見通し (通算14年間分)
    • 欧州市場の現状と見通し (通算14年間分)
  • 世界のマイクロバイオーム治療薬の市場規模 (通算14年間分)

第2章 世界のマイクロバイオーム治療薬市場:メーカー/ブランド間の競争状態

  • 売上高・市場シェア:メーカー別
  • 研究開発 (R&D) 投資額・シェア:メーカー別
  • 各メーカーの本社所在地、設立年度、製品種類
  • 市場競争の状態と傾向
    • 市場集中度
    • 上位3社・5社の市場シェア
    • 企業合併・買収 (M&A)、事業拡張

第3章 世界のマイクロバイオーム治療薬向け研究開発 (R&D) 投資額:地域別

  • マイクロバイオーム治療薬の開発企業の分布状況:地域別
  • R&D投資額・市場シェア:地域別 (過去6年間分)
  • R&D投資額・増加率 (過去6年間分)
  • 北米市場のR&D投資額・増加率 (過去6年間分)
  • 欧州市場のR&D投資額・増加率 (過去6年間分)

第4章 世界のマイクロバイオーム治療薬の市場規模:地域別 (通算14年間分)

  • 世界のマイクロバイオーム治療薬の消費量:地域別 (通算14年間分)
  • 北米諸国の市場規模 (通算14年間分)
  • 欧州諸国の市場規模 (通算14年間分)
  • アジア太平洋地域諸国の市場規模 (通算14年間分)

第5章 世界のマイクロバイオーム治療薬向け研究開発 (R&D) 投資額:用途別

  • マイクロバイオーム治療薬の開発企業と用途
  • 投資額の動向:用途別 (過去6年間分)
  • 生産量増加率:用途別 (過去6年間分)

第6章 マイクロバイオーム治療薬市場の分析:製品パイプライン別

  • マイクロバイオーム治療薬市場:パイプライン別
  • マイクロバイオーム治療薬の概要
    • 第III相 (フェーズ3) の製品:概略
      • SER-109
      • RBX2660
      • RP-G28
    • 第II相 (フェーズ2) の製品:概略
      • ribaxamase
      • SYN-010
      • EB8018
      • SGM-1019
      • Ammonia Oxidizing Bacteria (AOB)
      • C16G2
      • LACTIN-V
      • CBM588
    • 第I相 (フェーズ1) の製品:概略
      • SER-262
      • SER-287
      • ABI-H0731
      • Gemicel
      • AG014
      • VE303
      • Blautix
      • RBX2660
      • RBX7455

第7章 マイクロバイオーム治療薬の主要メーカーの分析

  • Seres Therapeutics
    • 企業プロファイル
    • 製品情報
    • 投資総額、研究開発 (R&D) 投資額
  • Assembly Biosciences
  • Synthetic Biologics
  • Interxon
  • PureTech
  • Synlogic
  • Enterome BioScience
  • 4D Pharma
  • Second Genome
  • AOBiome
  • C3. Jian
  • Rebiotix
  • MicroBiome Therapeutics LLC
  • Metabiomics
  • Ritter Pharmaceuticals
  • Symberix
  • OpenBiome
  • Azitra
  • Symbiotix Biotherapies
  • Osel
  • Metabogen

第8章 マイクロバイオーム治療薬の製造コストの分析

  • 研究開発 (R&D) 費用の分析
    • 治験費用
    • 資本化費用
  • 製造コスト構造の比率
    • 原材料
    • 人件費 (米国、欧州、アジア)
    • その他の費用:電気代、水道代 (米国、欧州、アジア)
    • 製造費用
  • マイクロバイオーム治療薬の製造工程の分析

第9章 関連産業、材料調達戦略、下流工程バイヤー

  • マイクロバイオーム治療薬の産業連関構造の分析
  • 上流工程からの原材料の調達
  • 下流工程部門のバイヤー

第10章 マーケティング戦略の分析、流通業者/取引業者

  • マーケティング・チャネル
    • 直接的マーケティング
    • 間接的マーケティング
    • マーケティング・チャネルの発展動向
  • 市場でのポジショニング
    • 価格戦略
    • ブランド戦略
    • 標的顧客
  • 流通業者/取引業者の一覧

第11章 市場への影響要因の分析

  • 技術進歩
  • 消費者のニーズ・選好の変化
  • 経済環境・政治環境の変化

第12章 世界のマイクロバイオーム治療薬市場の詳細予測

  • 研究開発 (R&D) 投資額・市場規模の予測
    • R&D投資額・増加率の予測 (今後6年間分)
    • 市場規模・成長率の予測 (今後9年間分)
  • R&D投資額の予測:地域別 (今後6年間分)
    • 北米のR&D投資額予測 (今後6年間分)
    • 欧州のR&D投資額予測 (今後6年間分)
  • 市場規模の予測:地域別 (今後9年間分)
    • 北米:市場規模の予測 (今後9年間分)
    • 欧州:市場規模の予測 (今後9年間分)
    • アジア太平洋地域:市場規模の予測 (今後9年間分)
  • R&D投資額の予測:用途別 (今後6年間分)
  • 市場規模の予測:用途別 (今後9年間分)

第13章 分析結果・結論

第14章 分析手法・情報源

図表

List of Tables and Figures

  • Figure Product Picture of Microbiome Therapeutics
  • Table Application of Microbiome Therapeutics
  • Table Global Microbiome Therapeutics R&D Investment (K USD) and Growth Rate Comparison by Types (2012-2022)
  • Figure Global Microbiome Therapeutics R&D Investment Market Share by Types in 2016
  • Figure C. difficile Infection (CDI) Examples
  • Figure Inflammatory Bowel Disease (IBD) Examples
  • Figure Orphan Drug Examples
  • Figure Immuno-oncology Examples
  • Table Microbiome Therapeutics Market by Pipeline
  • Figure Global Microbiome Therapeutics Market Size (M USD) Comparison and Growth Rate by Regions (2012-2025)
  • Table Microbiome Therapeutics Market Size (M USD) Comparison by Regions (2012-2025)
  • Figure North America Microbiome Therapeutics Market Size (M USD) and Growth Rate (2012-2025)
  • Figure Asia Pacific Microbiome Therapeutics Revenue (M USD) and Growth Rate (2012-2025)
  • Figure Europe Microbiome Therapeutics Revenue (M USD) and Growth Rate (2012-2025)
  • Figure Global Microbiome Therapeutics Market Size (M USD) Status and Outlook (2012-2025)
  • Table Global Microbiome Therapeutics Pipeline of Key Manufacturers in 2017
  • Table Global Microbiome Therapeutics R&D Investment (K USD) of Key Manufacturers (2016-2017)
  • Table Global Microbiome Therapeutics R&D Investment Share by Manufacturers (2016-2017)
  • Figure 2016 Microbiome Therapeutics R&D Investment Share by Manufacturers
  • Figure 2017 Microbiome Therapeutics R&D Investment Share by Manufacturers
  • Table Manufacturers Microbiome Therapeutics Headquarters and Established Date
  • Table Manufacturers Microbiome Therapeutics Product Category
  • Figure 2016 Microbiome Therapeutics R&D Investment Share by Manufacturers
  • Figure Microbiome Therapeutics R&D Investment Share of Top 3 Manufacturers
  • Figure Microbiome Therapeutics R&D Investment Share of Top 5 Manufacturers
  • Table Mergers & Acquisitions, Expansion
  • Table Global Microbiome Therapeutics Developer Distribution by Regions in 2017
  • Figure Global Microbiome Therapeutics Developer Distribution by Regions
  • Table Global Microbiome Therapeutics R&D Investment (K USD) by Regions (2012-2017)
  • Table Global Microbiome Therapeutics R&D Investment Market Share by Regions (2012-2017)
  • Figure Global Microbiome Therapeutics R&D Investment Market Share by Regions (2012-2017)
  • Figure 2016 Global Microbiome Therapeutics R&D Investment Market Share by Regions
  • Figure Global Microbiome Therapeutics R&D Investment (K USD) and Growth Rate (2012-2017)
  • Figure North America Microbiome Therapeutics R&D Investment (K USD) and Growth Rate (2012-2017)
  • Figure Europe Microbiome Therapeutics R&D Investment (K USD) and Growth Rate (2012-2017)
  • Table Global Microbiome Therapeutics Market Size (M USD) by Regions (2012-2018)
  • Table Global Microbiome Therapeutics Market Size (M USD) by Regions (2019-2025)
  • Table Global Microbiome Therapeutics Consumption Market Share by Regions (2012-2018)
  • Table Global Microbiome Therapeutics Consumption Market Share by Regions (2019-2025)
  • Figure Global Microbiome Therapeutics Consumption Market Share by Regions (2012-2025)
  • Figure 2025 Global Microbiome Therapeutics Consumption Market Share by Regions
  • Figure North America Microbiome Therapeutics Market Size (M USD) and Growth Rate (2012-2025)
  • Figure Europe Microbiome Therapeutics Market Size (M USD) and Growth Rate (2012-2025)
  • Figure Asia Pacific Microbiome Therapeutics Market Size (M USD) and Growth Rate (2012-2025)
  • Table Global Major Microbiome Therapeutics Developer Application
  • Table Global Microbiome Therapeutics R&D Investment (K USD) by Application (2012-2017)
  • Table Global Microbiome Therapeutics R&D Investment Share by Application (2012-2017)
  • Figure R&D Investment Market Share of Microbiome Therapeutics by Application (2012-2017)
  • Figure 2016 R&D Investment Market Share of Microbiome Therapeutics by Application
  • Figure Global Microbiome Therapeutics R&D Investment Growth by Application (2012-2017)
  • Table Global Microbiome Therapeutics Market by Pipeline
  • Table Phase 3 Product Introduction
  • Table Phase 2 Product Introduction
  • Figure Ammonia Oxidizing Bacteria (AOB) Pipeline
  • Figure LACTIN-V Pipeline
  • Figure CBM588 Pipeline
  • Table Phase 1 Product Introduction
  • Figure SER-262 Pipeline
  • Figure ABI-H0731 Pipeline
  • Figure Gemicel Pipeline
  • Figure VE303 Pipeline
  • Figure Blautix Pipeline
  • Figure RBX2660 Pipeline
  • Figure RBX7455 Pipeline
  • Table Seres Therapeutics Company Profile
  • Table Microbiome Therapeutics Product Information of Seres Therapeutics
  • Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Seres Therapeutics (2016 and 2017)
  • Table Assembly Biosciences Company Profile
  • Table Microbiome Therapeutics Product Information of Assembly Biosciences
  • Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Assembly Biosciences (2016 and 2017)
  • Table Synthetic Biologics Company Profile
  • Table Microbiome Therapeutics Product Information of Synthetic Biologics
  • Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Synthetic Biologics (2016 and 2017)
  • Table Interxon Company Profile
  • Table Microbiome Therapeutics Product Information of Interxon
  • Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Interxon (2016 and 2017)
  • Table PureTech Company Profile
  • Table Microbiome Therapeutics Product Information of PureTech
  • Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of PureTech (2016 and 2017)
  • Table Synlogic Company Profile
  • Table Microbiome Therapeutics Product Information of Synlogic
  • Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Synlogic (2016 and 2017)
  • Table Enterome BioScience Company Profile
  • Table Microbiome Therapeutics Product Information of Enterome BioScience
  • Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Enterome BioScience (2016 and 2017)
  • Table 4D Pharma Company Profile
  • Table Microbiome Therapeutics Product Information of 4D Pharma
  • Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of 4D Pharma (2016 and 2017)
  • Table Second Genome Company Profile
  • Table Microbiome Therapeutics Product Information of Second Genome
  • Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Second Genome (2016 and 2017)
  • Table AOBiome Company Profile
  • Table Microbiome Therapeutics Product Information of AOBiome
  • Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of AOBiome (2016 and 2017)
  • Table C3 Jian Company Profile
  • Table Microbiome Therapeutics Product Information of C3 Jian
  • Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of C3 Jian (2016 and 2017)
  • Table Rebiotix Company Profile
  • Table Microbiome Therapeutics Product Information of Rebiotix
  • Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Rebiotix (2016 and 2017)
  • Table MicroBiome Therapeutics LLC Company Profile
  • Table Microbiome Therapeutics Product Information of MicroBiome Therapeutics LLC
  • Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of MicroBiome Therapeutics LLC (2016 and 2017)
  • Table Metabiomics Company Profile
  • Table Microbiome Therapeutics Product Information of Metabiomics
  • Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Metabiomics (2016 and 2017)
  • Table Ritter Pharmaceuticals Company Profile
  • Table Microbiome Therapeutics Product Information of Ritter Pharmaceuticals
  • Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Ritter Pharmaceuticals (2016 and 2017)
  • Table Symberix Company Profile
  • Table Microbiome Therapeutics Product Information of Symberix
  • Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Symberix (2016 and 2017)
  • Table OpenBiome Company Profile
  • Table Microbiome Therapeutics Product Information of OpenBiome
  • Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of OpenBiome (2016 and 2017)
  • Table Azitra Company Profile
  • Table Microbiome Therapeutics Product Information of Azitra
  • Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Azitra (2016 and 2017)
  • Table Symbiotix Biotherapies Company Profile
  • Table Microbiome Therapeutics Product Information of Symbiotix Biotherapies
  • Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Symbiotix Biotherapies (2016 and 2017)
  • Table Osel Company Profile
  • Table Microbiome Therapeutics Product Information of Osel
  • Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Osel (2016 and 2017)
  • Table Metabogen Company Profile
  • Table Microbiome Therapeutics Product Information of Metabogen
  • Table Microbiome Therapeutics Investment (K USD), R&D Investment (K USD) and Product Information of Metabogen (2016 and 2017)
  • Figure typical phases from research to the market for a drug candidate
  • Table Out-of-pocket Preclinical and Clinical Period Cost per Investigational Biopharmaceutical Compound
  • Table Capitalized Preclinical and Clinical Period costs per Investigational Biopharmaceutical Compound
  • Figure Manufacturing Cost Structure of Microbiome Therapeutics
  • Figure Assessment of API Manufacturing Cost By Region
  • Figure USA Labor Cost Analysis 2012-2016
  • Figure Cost of Employing a Factory Worker
  • Figure 2016 Estimated Labour Costs for the Whole Economy in Europe
  • Figure Monthly Minimum Wages in Asia 2016
  • Figure China Labor Costs 2013-2016
  • Table Average Price of Electricity to Ultimate Customers 2007-2016
  • Figure Electricity Prices for Household Consumers in 2016
  • Figure Summary of the Driving Assumptions
  • Figure Industrial Electric Rates 2016 (PER KWH)
  • Figure Manufacturing Process Analysis of Microbiome Therapeutics
  • Figure Microbiome Therapeutics Industrial Chain Analysis
  • Table Major Buyers of Microbiome Therapeutics
  • Figure Setting Pricing Policy
  • Table Distributors/Traders List
  • Table Predominant Bacterial Phyla in the Human Body
  • Figure Global GDP Growth Rate for 2016
  • Figure US GDP 2006-2016 (Billion USD)
  • Figure US CPI Change 2016-2017
  • Figure EU GDP 2006-2016 (Billion USD)
  • Figure EU CPI Change 2012-2016
  • Figure Germany GDP 2006-2016 (Billion USD)
  • Figure Germany CPI Change 2016-2017
  • Figure UK GDP 2006-2016 (Billion USD)
  • Figure UK CPI Change 2016-2017
  • Figure Italy GDP 2006-2016 (Billion USD)
  • Figure Italy CPI Change 2016-2017
  • Figure Japan GDP 2006-2016 (Billion USD)
  • Figure Japan CPI Change 2012-2016
  • Figure China GDP 2006-2016 (Billion USD)
  • Figure China CPI Change 2016-2017
  • Figure Global Microbiome Therapeutics R&D Investment (K USD) and Growth Rate Forecast (2017-2022)
  • Figure Global Microbiome Therapeutics Market Size (M USD) and Growth Rate Forecast (2017-2025)
  • Table Global Microbiome Therapeutics R&D Investment (K USD) Forecast by Regions (2017-2022)
  • Figure Global Microbiome Therapeutics R&D Investment Market Share Forecast by Regions (2017-2022)
  • Figure North America Microbiome Therapeutics R&D Investment (K USD) and Growth Rate Forecast (2017-2022)
  • Figure Europe Microbiome Therapeutics R&D Investment (K USD) and Growth Rate Forecast (2017-2022)
  • Table Global Microbiome Therapeutics Market Size (M USD) Forecast by Regions (2018-2025)
  • Figure Global Microbiome Therapeutics Market Size Share Forecast by Regions (2018-2025)
  • Figure North America Microbiome Therapeutics Market Size (M USD) and Growth Rate Forecast (2018-2025)
  • Figure Europe Microbiome Therapeutics Market Size (M USD) and Growth Rate Forecast (2018-2025)
  • Figure Asia Pacific Microbiome Therapeutics Market Size (M USD) and Growth Rate Forecast (2018-2025)
  • Table Global Microbiome Therapeutics R&D Investment (K USD) Forecast by Application (2017-2022)
  • Figure Global Microbiome Therapeutics R&D Investment Share Forecast by Type (2017-2022)
  • Table Global Microbiome Therapeutics Market Size (M USD) Forecast by Application (2018-2025)
  • Figure Global Microbiome Therapeutics Consumption Forecast by Application (2018-2025)
  • Table Research Programs/Design for This Report
  • Figure Bottom-up and Top-down Approaches for This Report
  • Figure Data Triangulation
  • Table Key Data Information from Secondary Sources
  • Table Key Data Information from Primary Sources
目次

This report studies the Microbiome Therapeutics market status and outlook of global and major regions, from angles of players, regions, product types and end industries; this report analyzes the top players in global and major regions, and splits the Microbiome Therapeutics market by product type and applications/end industries.

In the last several years, global market of microbiome therapeutics developed rapidly, with an average growth rate of 98%. In 2017, global market size of microbiome therapeutics is nearly 14 M USD.

For developing product, there are 2 products in Phase 3, 7 products in Phase 2, 8 products in Phase 1 and 17 products in Preclinical. The total investment for Microbiome Therapeutics developing is around 293 M USD in 2017.

The major players in global Microbiome Therapeutics market include:

  • Seres Therapeutics
  • Assembly Biosciences
  • Synthetic Biologics
  • Interxon
  • PureTech
  • Synlogic
  • Enterome BioScience
  • 4D Pharma
  • Second Genome
  • AOBiome
  • C3 Jian
  • Rebiotix
  • MicroBiome Therapeutics LLC
  • Metabiomics
  • Ritter Pharmaceuticals
  • Symberix
  • OpenBiome
  • Azitra
  • Symbiotix Biotherapies
  • Osel
  • Metabogen

Geographically, this report is segmented into several key regions, with market size and R&D investment of microbiome therapeutics in these regions, from 2012 to 2025 (forecast), covering:

  • North America
  • Europe
  • Asia Pacific
  • Other

On the basis on the end users/applications, this report covers:

  • C. difficile Infection (CDI)
  • Inflammatory Bowel Disease (IBD)
  • Orphan Drug
  • Immuno-oncology
  • Others

Table of Contents

1. Microbiome Therapeutics Market Overview

  • 1.1. Microbiome Therapeutics Product Overview
  • 1.2. Microbiome Therapeutics Segment by Application
    • 1.2.1. Global Microbiome Therapeutics R&D Investment and Growth Rate Comparison by Application (2012-2022)
    • 1.2.2. Global Microbiome Therapeutics R&D Investment Market Share by Types in 2016
    • 1.2.3. C. difficile Infection (CDI)
    • 1.2.4. Inflammatory Bowel Disease (IBD)
    • 1.2.5. Orphan Drug
    • 1.2.6. Immuno-oncology
  • 1.3. Microbiome Therapeutics Market by Pipeline
  • 1.4. Global Microbiome Therapeutics Market by Regions (2012-2022)
    • 1.4.1. Global Microbiome Therapeutics Market Size and Growth Rate Comparison by Regions (2012-2022)
    • 1.4.2. North America Microbiome Therapeutics Status and Prospect (2012-2025)
    • 1.4.3. Asia Pacific Microbiome Therapeutics Status and Prospect (2012-2025)
    • 1.4.4. Europe Microbiome Therapeutics Status and Prospect (2012-2025)
  • 1.5. Global Microbiome Therapeutics Market Size (2012-2025)

2. Global Microbiome Therapeutics Market Competition by Manufacturers/Brand

  • 2.1. Global Microbiome Therapeutics Sales and Share by Manufacturers
  • 2.2. Global Microbiome Therapeutics R&D Investment and Share by Manufacturers (2012-2017)
  • 2.3. Manufacturers Microbiome Therapeutics Headquarters, Established Date, Product Types
  • 2.4. Microbiome Therapeutics Market Competitive Situation and Trends
    • 2.4.1. Microbiome Therapeutics R&D Investment Concentration Rate
    • 2.4.2. Microbiome Therapeutics R&D Investment Share of Top 3 and Top 5 Manufacturers
    • 2.4.3. Mergers & Acquisitions, Expansion

3. Global Microbiome Therapeutics R&D Investment by Regions (2012-2017)

  • 3.1. Global Microbiome Therapeutics Developer Distribution by Regions
  • 3.2. Global Microbiome Therapeutics R&D Investment and Market Share by Regions (2012-2017)
  • 3.3. Global Microbiome Therapeutics R&D Investment and Growth Rate (2012-2017)
  • 3.4. North America Microbiome Therapeutics R&D Investment and Growth Rate (2012-2017)
  • 3.5. Europe Microbiome Therapeutics R&D Investment and Growth Rate (2012-2017)

4. Global Microbiome Therapeutics Market Size by Regions (2012-2025)

  • 4.1. Global Microbiome Therapeutics Consumption by Regions (2012-2025)
  • 4.2. North America Microbiome Therapeutics Market Size (2012-2025)
  • 4.3. Europe Microbiome Therapeutics Market Size (2012-2025)
  • 4.4. Asia Pacific Microbiome Therapeutics Market Size (2012-2025)

5. Global Microbiome Therapeutics R&D Investment by Application

  • 5.1. Global Major Microbiome Therapeutics Developer Application
  • 5.2. Global Microbiome Therapeutics Investment by Application (2012-2017)
  • 5.3. Global Microbiome Therapeutics Production Growth by Application (2012-2017)

6. Microbiome Therapeutics Market Analysis by Product Pipeline

  • 6.1. Microbiome Therapeutics Market by Pipeline
  • 6.2. Microbiome Therapeutics Product Introduction
    • 6.2.1. Phase 3 Product Introduction
      • 6.2.1.1. SER-109
      • 6.2.1.2. RBX2660
      • 6.2.1.3. RP-G28
    • 6.2.2. Phase 2 Product Introduction
      • 6.2.2.1. ribaxamase
      • 6.2.2.2. SYN-010
      • 6.2.2.3. EB8018
      • 6.2.2.4. SGM-1019
      • 6.2.2.5. Ammonia Oxidizing Bacteria (AOB)
      • 6.2.2.6. C16G2
      • 6.2.2.7. LACTIN-V
      • 6.2.2.8. CBM588
    • 6.2.3. Phase 1 Product Introduction
      • 6.2.3.1. SER-262
      • 6.2.3.2. SER-287
      • 6.2.3.3. ABI-H0731
      • 6.2.3.4. Gemicel
      • 6.2.3.5. AG014
      • 6.2.3.6. VE303
      • 6.2.3.7. Blautix
      • 6.2.3.8. RBX2660
      • 6.2.3.9. RBX7455

7. Analysis of Microbiome Therapeutics Industry Key Manufacturers

  • 7.1. Seres Therapeutics
    • 7.1.1. Company Profile
    • 7.1.2. Product Information
    • 7.1.3. Investment and Investment of R&D
  • 7.2. Assembly Biosciences
    • 7.2.1. Company Profile
    • 7.2.2. Product Information
    • 7.2.3. Investment and Investment of R&D
  • 7.3. Synthetic Biologics
    • 7.3.1. Company Profile
    • 7.3.2. Product Information
    • 7.3.3. Investment and Investment of R&D
  • 7.4. Interxon
    • 7.4.1. Company Profile
    • 7.4.2. Product Information
    • 7.4.3. Investment and Investment of R&D
  • 7.5. PureTech
    • 7.5.1. Company Profile
    • 7.5.2. Product Information
    • 7.5.3. Investment and Investment of R&D
  • 7.6. Synlogic
    • 7.6.1. Company Profile
    • 7.6.2. Product Information
    • 7.6.3. Investment and Investment of R&D
  • 7.7. Enterome BioScience
    • 7.7.1. Company Profile
    • 7.7.2. Product Information
    • 7.7.3. Investment and Investment of R&D
  • 7.8. 4D Pharma
    • 7.8.1. Company Profile
    • 7.8.2. Product Information
    • 7.8.3. Investment and Investment of R&D
  • 7.9. Second Genome
    • 7.9.1. Company Profile
    • 7.9.2. Product Information
    • 7.9.3. Investment and Investment of R&D
  • 7.10. AOBiome
    • 7.10.1. Company Profile
    • 7.10.2. Product Information
    • 7.10.3. Investment and Investment of R&D
  • 7.11. C3. Jian
    • 7.11.1. Company Profile
    • 7.11.2. Product Information
    • 7.11.3. Investment and Investment of R&D
  • 7.12. Rebiotix
    • 7.12.1. Company Profile
    • 7.12.2. Product Information
    • 7.12.3. Investment and Investment of R&D
  • 7.13. MicroBiome Therapeutics LLC
    • 7.13.1. Company Profile
    • 7.13.2. Product Information
    • 7.13.3. Investment and Investment of R&D
  • 7.14. Metabiomics
    • 7.14.1. Company Profile
    • 7.14.2. Product Information
    • 7.14.3. Investment and Investment of R&D
  • 7.15. Ritter Pharmaceuticals
    • 7.15.1. Company Profile
    • 7.15.2. Product Information
    • 7.15.3. Investment and Investment of R&D
  • 7.16. Symberix
    • 7.16.1. Company Profile
    • 7.16.2. Product Information
    • 7.16.3. Investment and Investment of R&D
  • 7.17. OpenBiome
    • 7.16.1. Company Profile
    • 7.16.2. Product Information
    • 7.16.3. Investment and Investment of R&D
  • 7.18. Azitra
    • 7.18.1. Company Profile
    • 7.18.2. Product Information
    • 7.18.3. Investment and Investment of R&D
  • 7.19. Symbiotix Biotherapies
    • 7.19.1. Company Profile
    • 7.19.2. Product Information
    • 7.19.3. Investment and Investment of R&D
  • 7.20. Osel
    • 7.20.1. Company Profile
    • 7.20.2. Product Information
    • 7.20.3. Investment and Investment of R&D
  • 7.21. Metabogen
    • 7.21.1. Company Profile
    • 7.21.2. Product Information
    • 7.21.3. Investment and Investment of R&D

8. Microbiome Therapeutics Manufacturing Cost Analysis

  • 8.1. Microbiome Therapeutics R&D Cost Analysis

8.1.1Clinical Phase Costs 101

    • 8.1.2. Capitalized Costs
  • 8.2. Proportion of Manufacturing Cost Structure
    • 8.2.1. Raw Materials
    • 8.2.2. Labor Cost Analysis
      • 8.2.2.1. USA Labor Cost Analysis
      • 8.2.2.2. Europe Labor Costs Analysis
      • 8.2.2.3. Asia Labor Costs Analysis
    • 8.2.3. Other Costs Analysis
      • 8.2.3.1. USA Cost of Electricity Analysis
      • 8.2.3.2. USA Water Cost Analysis
      • 8.2.3.3. Europe Cost of Electricity Analysis
      • 8.2.3.4. Europe Water Cost Analysis
      • 8.2.3.5. China Cost of Electricity Analysis
      • 8.2.3.6. China Water Cost Analysis
    • 8.2.4. Manufacturing Expenses
  • 8.3. Manufacturing Process Analysis of Microbiome Therapeutics

9. Industrial Chain, Sourcing Strategy and Downstream Buyers

  • 9.1. Microbiome Therapeutics Industrial Chain Analysis
  • 9.2. Upstream Raw Materials Sourcing
  • 9.3. Downstream Buyers

10. Marketing Strategy Analysis, Distributors/Traders

  • 10.1. Marketing Channel
    • 10.1.1. Direct Marketing
    • 10.1.2. Indirect Marketing
    • 10.1.3. Marketing Channel Development Trend
  • 10.2. Market Positioning
    • 10.2.1. Pricing Strategy
    • 10.2.2. Brand Strategy
    • 10.2.3. Target Client
  • 10.3. Distributors/Traders List

11. Market Effect Factors Analysis

  • 11.1. Technology Progress
  • 11.2. Consumer Needs/Customer Preference Change
  • 11.3. Economic/Political Environmental Change

12. Global Microbiome Therapeutics Market Forecast (2017-2022)

  • 12.1. Global Microbiome Therapeutics R&D Investment and Market Size Forecast
    • 12.1.1. Global Microbiome Therapeutics R&D Investment and Growth Rate Forecast (2017-2022)
    • 12.1.2. Global Microbiome Therapeutics Market Size and Growth Rate Forecast (2017-2025)
  • 12.2. Global Microbiome Therapeutics R&D Investment Forecast by Regions (2017-2022)
    • 12.2.1. North America Microbiome Therapeutics R&D Investment Forecast (2017-2022)
    • 12.2.2. Europe Microbiome Therapeutics R&D Investment Forecast (2017-2022)
  • 12.3. Global Microbiome Therapeutics Market Size Forecast by Regions (2018-2025)
    • 12.3.1. North America Microbiome Therapeutics Market Size Forecast (2018-2025)
    • 12.3.2. Europe Microbiome Therapeutics Market Size Forecast (2018-2025)
    • 12.3.3. Asia Pacific Microbiome Therapeutics Market Size Forecast (2018-2025)
  • 12.4. Global Microbiome Therapeutics R&D Investment Forecast by Application (2017-2022)
  • 12.5. Global Microbiome Therapeutics Market Size Forecast by Application (2018-2025)

13. Research Findings and Conclusion

14. Methodology and Data Source

  • 14.1. Methodology/Research Approach
    • 14.1.1. Research Programs/Design
    • 14.1.2. Market Size Estimation
    • 14.1.3. Market Breakdown and Data Triangulation
  • 14.2. Data Source
    • 14.2.1. Secondary Sources
    • 14.2.2. Primary Sources
  • 14.3. Disclaimer
  • 14.4. Author List
Back to Top